Compare prices and buy CJC-1295 No DAC from 30 research peptide vendors - also called suppliers or sources. Updated daily.
A 29-amino-acid GHRH analog corresponding to the 1-29 fragment of human GHRH with four substitutions (D-Ala2 / Gln8 / Ala15 / Leu27), molecular formula C152H252N44O42. Also marketed as "Modified GRF 1-29" or "Mod GRF 1-29." Lacks the albumin-binding Drug Affinity Complex of the DAC form, which the CJC-1295 name originally denoted. GHRH analogs act at the GHRH receptor on pituitary somatotrophs, but FDA reported finding no studies establishing that the no-DAC free base or its acetate are pharmacologically active. The published human and rodent data concern the DAC form. Commonly sold blended with ipamorelin, a ghrelin-receptor agonist, a market convention rather than a demonstrated pharmacological pairing. It is not FDA-approved.
For research purposes only. Not medical advice.
CJC-1295 No DAC is a synthetic 29-amino-acid analog of growth hormone-releasing hormone, sequence Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2, molecular formula C152H252N44O42, molecular weight 3367.95.
It is sermorelin's backbone with four residues exchanged: D-alanine at position 2, glutamine at 8, alanine at 15 and leucine at 27, in place of the alanine, asparagine, glycine and methionine of native GHRH(1-29). Three of them target a stability liability. The D-alanine is a change shown to resist DPP-4 cleavage in other peptides, the glutamine replaces an asparagine prone to rearrangement, and the leucine replaces an oxidizable methionine. FDA noted that how far the substitutions add to stability remains to be determined.
The name, though, belongs to the other compound. ConjuChem Biotechnologies' CJC-1295 was the version carrying a Drug Affinity Complex, a maleimidopropionyl-lysine that bonds covalently to albumin. The tetrasubstituted core without that group is what this row indexes, and it took the CJC-1295 name afterward, by subtraction. CJC-1295 With DAC is indexed here as a separate row.
GHRH analogs bind the GHRH receptor on pituitary somatotrophs and prompt the gland to release its own growth hormone in pulses. Sermorelin, tesamorelin and both CJC-1295 rows belong to that family, while ipamorelin, GHRP-2, GHRP-6 and hexarelin reach a comparable pituitary output through the ghrelin receptor instead.
The direct evidence for this particular molecule is thin. In its 2024 review FDA reported that neither the nominations nor its own literature search identified studies establishing whether CJC-1295 free base or CJC-1295 acetate are pharmacologically active. The published growth-hormone-secretagogue activity in rodents belongs to the DAC form. The mechanism above is an inference from the receptor family, not a result reported for the material sold under this name.
FDA's 2024 review found no clinical safety information on the no-DAC form, and no ClinicalTrials.gov record names the no-DAC form as of October 2026. The published human studies, by Ionescu and Frohman and by Teichman and colleagues, both in 2006, used the DAC version. ConjuChem withdrew CJC-1295 DAC from clinical development in 2006 after a subject died during a Phase 2 study in HIV-associated lipodystrophy.
The no-DAC compound's first appearance in the literature is not a development program at all. Henninge and colleagues reported in 2010 on an unknown pharmaceutical preparation seized by Norwegian police and customs in 2009, whose mass spectrometry matched the CJC-1295 sequence without the DAC modification. FDA wrote that the paper appears to be the first reference to CJC-1295 without DAC in the literature.
CJC-1295 was placed in Category 2 of FDA's interim bulk drug substances policy, the designation for substances that may present significant safety risks. The recorded concerns are immunogenicity for certain routes of administration, peptide-related impurities and characterization difficulty, and serious adverse events including increased heart rate and systemic vasodilatory reaction, against limited clinical data.
In September 2024, FDA removed CJC-1295 from Category 2 because the nominators had withdrawn their nominations. That did not end the review. FDA carried CJC-1295 to the Pharmacy Compounding Advisory Committee at its own discretion, and on December 4, 2024 the committee took up five CJC-1295-related substances for the use FDA evaluated, growth hormone deficiency, and voted down every one.
As of October 2026, CJC-1295 appears only in the "nominated but withdrawn" table of FDA's Category 2 page, which keeps the safety text with the entry. The World Anti-Doping Agency names CJC-1295 under S2.2.4, prohibited at all times.
FDA counted at least nine names in circulation for five distinct CJC-1295 bulk drug substances, and called the inconsistency a safety risk in its own right. The two nominations it reviewed show the problem in miniature: both cited UNII code 62RC32V9N7, which corresponds to the DAC form, while the certificate of analysis attached to one of them matched the no-DAC free base instead. FDA also recorded that the Global Substance Registration System entry for CJC-1295 free base reports the structure of CJC-1295 DAC.
PeptideScouter indexes CJC-1295 No DAC vials per milligram and verifies identity against its molecular formula rather than the product title.
Yes. They are two names for one substance: the first 29 amino acids of growth hormone-releasing hormone carrying four substitutions, D-alanine at position 2, glutamine at 8, alanine at 15 and leucine at 27, with molecular formula C152H252N44O42. Modified GRF 1-29 describes what the molecule is, while CJC-1295 No DAC describes it by what it lacks relative to the ConjuChem compound that originally carried the CJC-1295 name. Vendors use both, along with CJC-1295 W/O DAC and a bare CJC-1295, and all of them route to this row.
The DAC form adds a Drug Affinity Complex, a maleimidopropionyl-lysine appended to the 29-residue core, which bonds covalently to the cysteine 34 residue of circulating albumin. That changes the molecule measurably: formula C165H269N47O46 and molecular weight 3647.95 for the DAC form against C152H252N44O42 and 3367.95 without it. In the published human studies of the DAC version the estimated half-life ran to several days. FDA noted that direct evidence is lacking that the DAC group is what extends it, and that showing the DAC form's half-life is longer than the no-DAC form's would be needed to support that. PeptideScouter indexes them as separate rows, and vendors price them at different tiers.
Yes. The Pharmacy Compounding Advisory Committee took up five CJC-1295-related bulk drug substances on December 4, 2024, for the use FDA evaluated, growth hormone deficiency. All five were rejected: CJC-1295 free base by 0 in favor to 13 against and CJC-1295 acetate by 1 to 12, along with the three CJC-1295 DAC forms. FDA had recommended against including any of them on the 503A bulks list.
Not on its own. The published human studies bearing the CJC-1295 name, by Ionescu and Frohman and by Teichman and colleagues, both appearing in 2006, used the DAC version rather than this one. ConjuChem withdrew that compound from clinical development in 2006, after a subject died during a Phase 2 study in HIV-associated lipodystrophy. Reviewing the compound in 2024, FDA reported that it identified no studies establishing whether CJC-1295 free base or CJC-1295 acetate are even pharmacologically active.
CJC-1295 No DAC is sold by 30 research peptide vendors indexed on PeptideScouter, with 52 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
28 of the 30 indexed vendors currently have CJC-1295 No DAC in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Alpha Peptides currently lists CJC-1295 No DAC at $3.13/mg, the lowest listed price across 30 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $2.82/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 30 vendors listing CJC-1295 No DAC publish a PeptideScouter code, worth 5% to 50% off. Applied, the lowest effective price falls from $3.13/mg listed to $2.82/mg at Alpha Peptides. Each vendor's code is shown beside its price in the table above.
CJC-1295 No DAC ranges from $3.13/mg to $21.48/mg across 52 listings from 30 research peptide vendors, normalized to USD per milligram and refreshed daily.
30 research peptide vendors currently list CJC-1295 No DAC on PeptideScouter, with 28 in stock right now. We track 52 listings across size and kit variants.
CJC-1295 No DAC's CAS Registry Number is 446036-97-1. It is also sold as CJC-1295, CJC-1295 W/O DAC, CJC-1295 (No DAC).
